The global Hemochromatosis (Iron overload) diseases treatment market is projected to grow at a CAGR of 2.84% during the forecast period to reach US$30.698 billion by 2027, from US$25.241 billion in 2020.
The unusual accumulation of iron in the parenchymal organ is known as hemochromatosis. The overaccumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a condition in which iron accumulates abnormally in parenchymal organs. Excessive absorption of iron in the body causes organ toxicity. Hemochromatosis can be detected using chest x-rays, echocardiography, CT scans, and possibly imaging tests such as MRI. Patients with hemochromatosis can be evaluated using diagnostic endoscopy, skin endoscopy, and liver biopsy.
The hemochromatosis treatment market is driven primarily by dramatic lifestyle changes, which are becoming more stressful today. This can lead to many mutations that cause hemochromatosis and, ultimately, iron accumulation. Rapid climate change can also cause hemochromatosis. Lack of awareness of the disease and signs of less apparent symptoms can limit the hemochromatosis treatment market.
Primary hemochromatosis (hereditary) and secondary hemochromatosis are the two most common types of hemochromatosis. Secondary hemochromatosis develops because of anaemia, liver disease, or other illnesses such as heavy blood transfusions. Hemochromatosis is more common in men than women because menstruation causes monthly blood loss in women. As a result, women accumulate iron more slowly than men.
If hemochromatosis isn't regarded and handled early on, it may broaden to the most critical issues consisting of liver damage, diabetes, arthritis, reproductive issues, and cardiovascular disease. Blood investigation and thorough bodily examinations are used to diagnose it. Nowadays, a considerable lifestyle change that has grown extra traumatic may also result in a slew of mutations that result in hemochromatosis and iron accumulation. Hemochromatosis also can result from drastic climate changes.
Too much iron is harmful to the body, and high levels of iron can give seriously harm tissues and organs over time, leading to diseases like cirrhosis (damage to the liver), carcinoma (liver cancer), heart issues, arthritis (joint pain), as well as diabetes.
Hemochromatosis (Iron overload disease) has been treated by phlebotomy, chelation therapy, and surgery. By 2027, the phlebotomy treatment segment is expected to have the largest market share. Phlebotomy, which requires taking out excess iron from the blood, is used to cure hemochromatosis. This procedure has kept the iron blood levels in check by taking blood from the patient's body regularly. It is the same as blood donation. Phlebotomy is simple, low-cost, and risk-free. Like regular blood donation, phlebotomy is primarily performed in blood banks.
Early disease detection and increased financial investment in Research & Development activities by industry participants are expected to drive the growth of the global hemochromatosis treatment market during the forecasted period. Increasing R&D technologies with high-tech treatment options, on the other hand, will heighten numerous opportunities that will begin to germinate in the global hemochromatosis treatment market during the forecast period. The presence of anaemia in women is expected to drive the growth of the hemochromatosis treatment market. According to WHO, the anaemia prevalence in reproductive-age women was 29.9 percent, 36.5 percent in pregnant women, and 29.6 percent in non-pregnant women in 2019. The percentage varies by region, with the highest increase in percentage seen in Southern Asia, Central Asia, and Sub-Saharan Africa, and the lowest in Europe and North America.
To accommodate patients with COVID-19 and limit the transmission of disease, acute hospital services have been significantly reorganized. Non-essential treatment was temporarily halted for months for patients, and outpatient care was transformed into telehealth, an approach supported by expert panel guidelines. These required reforms focused on what care facility could be provided during the pandemic and which services could be detoured to the community. This was a workable approach for many chronically ill patients, and they benefited from advanced remote monitoring systems. However, for patients who require physical hospital visits for treatment, this advancement was unfortunately inapplicable to their situation. This has subsequently impacted the global hemochromatosis (iron overloaded) treatment market.
Regional Analysis
Due to the advancements in hemochromatosis diagnosis methods, North America is expected to have the largest market share in the hemochromatosis treatment industry. Europe is expected to be followed by North America due to increased invested capital in hemochromatosis treatment research and development. While the Asia Pacific is expected to grow from 2021 to 2027 owing to the increasingly significant presence of major players in the market and rising treatment costs and availability. During the forecast period, Asia Pacific is expected to proliferate owing to global population movements, rising living standards, and a more technologically inclined population, which are causing genetic changes that may cause hemochromatosis treatment market in the Asia Pacific region.
| Report Metric | Details |
| Market size value in 2020 | US$25.241 billion |
| Market size value in 2027 | US$30.698 billion |
| Growth Rate | CAGR of 2.84% from 2020 to 2027 |
| Base year | 2020 |
| Forecast period | 2022–2027 |
| Forecast Unit (Value) | USD Billion |
| Segments covered | Type, Treatment, End-User, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Fresenius Kabi, Genzyme Corporation, Protagonist Therapeutics, Silence Therapeutics, Disc Medicine, Bond Biosciences |
| Customization scope | Free report customization with purchase |
Key Segmentation
Frequently Asked Questions (FAQs)
Q1. What is the size of the global hemochromatosis (Iron overload) disease treatment market?
A1. Hemochromatosis (Iron Overload) Disease Treatment Market was valued at US$25.241 billion in the year 2020.
Q2. What will be the hemochromatosis disease treatment market size by 2027?
A2. The global hemochromatosis disease treatment market is projected to reach a market size of US$30.698 billion by 2027.
Q3. What are the growth prospects for the hemochromatosis (Iron overload) disease treatment market?
A3. The hemochromatosis (Iron overload) diseases treatment market is projected to grow at a CAGR of 2.84% during the forecast period.
Q4. What factors are anticipated to drive the hemochromatosis disease treatment market growth?
A4. The hemochromatosis treatment market is driven primarily by dramatic lifestyle changes, which are becoming more stressful today.
Q5. Which region holds the maximum market share in the hemochromatosis disease treatment market?
A5. North America is expected to have the largest share in the hemochromatosis disease treatment market due to the advancements in hemochromatosis diagnosis methods.
Fresenius Kabi
Genzyme Corporation
Protagonist Therapeutics
Disc Medicine
Bond Biosciences
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.